HomeMarket NewsMicro Cap StocksVigil Neuroscience Stock Plummets 37.1% After Disappointing Neurological Disease Trial Results

Vigil Neuroscience Stock Plummets 37.1% After Disappointing Neurological Disease Trial Results

Actionable Trade Ideas

always free

vigl

Vigil Neuroscience IncΒ VIGL is witnessing a brutal market reaction today, with shares plummeting by a massive 37.1% after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurological condition characterized by changes toΒ certain brain areas.

The company’s attempt to paint a positive picture by highlighting favorable safety and tolerability profile turned out to be a flimsy veil over the disappointing outcome of the trial. The interim data represented the first six patients following six months of treatment with 20 mg/kg of iluzanebart (formerly VGL101), which did not live up to the market’s expectations and led to a massive sell-off of shares.

Additionally, the company reported findings from its ongoing natural history study, ILLUMINATE, that provided insights on MRI and NfL biomarkers but failed to offer any respite as the market frets over the significant setbacks in the Phase 2 trial.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.